NYRADA INC (ASX:NYR) 54 14. Subsidiaries 2024 ownership interest 2023 ownership interest Nyrada Pty Ltd 100% 100% Norbio No.2 Pty Ltd 100% 100% Cardio Therapeutics Pty Ltd 100% 100% 15. Events after reporting period No matters or circumstances have arisen since 30 June 2024 that has significantly affected, or may significantly affect the Consolidated Entity's operations, the results of those operations, or the Consolidated Entity's state of affairs in future financial years. 16. Cash flow information Reconciliation of loss after income tax to net cash used in operating activities 2024 2023 $ $ Loss after income tax expense for the year (1,391,309) (7,781,692) Adjustments for: Depreciation & amortisation 5,183 6,534 Share-based payments 358,074 541,214 Change in operating assets and liabilities Decrease/(increase) in trade and other receivables 312,890 (264,140) Increase/(decrease) in trade and other payables (62,981) 245,433 Increase/(decrease) in employee benefits 11,848 53,260 (766,295) (7,199,391) Reconciliation of Cash Cash at the end of financial year as included in the statement of cash flows is reconciled to the related items in the statement of financial position as follows: 2024 2023 $ $ Cheque account 56,034 196,729 USD account 388 671 Saving bonus 2,212,952 3,511,361 Term deposit 2,500,000 - 4,769,374 3,708,761
RkJQdWJsaXNoZXIy MjE2NDg3